Liang, Shun-Qing

Improved prime editors enable pathogenic allele correction and cancer modelling in adult mice

Liu, P., Liang, S.-Q., Zheng, C., Mintzer, E., Zhao, Y. G., Ponnienselvan, K., Mir, A., Sontheimer, E. J., Gao, G., Flotte, T. R., et al. (2021) · Nature Communications

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 273

New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

Yang, H., Liang, S.-Q., Schmid, R. A., & Peng, R.-W. (2019) · Frontiers in Oncology

Lung Cancer Treatments and MutationsProtein Kinase Regulation and GTPase Signaling

Cited by 129

Tissue-restricted genome editing in vivo specified by microRNA-repressible anti-CRISPR proteins

Lee, J., Mou, H., Ibraheim, R., Liang, S.-Q., Liu, P., Xue, W., & Sontheimer, E. J. (2019) · RNA

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 100

HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer

Yang, H., Liang, S.-Q., Xu, D., Yang, Z., Marti, T. M., Gao, Y., Kocher, G. J., Zhao, H., Schmid, R. A., & Peng, R.-W. (2019) · Oncogenesis

Lung Cancer Treatments and MutationsEndoplasmic Reticulum Stress and Disease

Cited by 58

mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene

PI3K/AKT/mTOR signaling in cancerLung Cancer Treatments and Mutations

Cited by 55

Genome-wide detection of CRISPR editing in vivo using GUIDE-tag

Liang, S.-Q., Liu, P., Smith, J. L., Mintzer, E., Maitland, S., Dong, X., Yang, Q., Lee, J., Haynes, C. M., Zhu, L. J., et al. (2022) · Nature Communications

CRISPR and Genetic EngineeringRNA regulation and disease

Cited by 54